September 2023 Insights: greater patient centricity, shipping considerations for specialty drugs, and more

September 2023 Insights: greater patient centricity, shipping considerations for specialty drugs, and more


Bringing drugs to market earlier with greater patient centricity

by Andrea Zobel

The increasing demand for diversity and inclusion in clinical trials, and the need to reach patients wherever they may be, is now being addressed with the help of direct-to-patient (DtP) shipments. In a recent podcast, Andrea Zobel, Senior Director of Personalized Supply Chain discussed how the industry is shifting towards a more patient-centric approach, streamlining the clinical trial process, and bringing life-saving drugs to market faster.

What are DtP shipments?

DtP shipments refer to the practice of shipping clinical trial materials directly to a participant’s home. This model makes it easier for patients to partake in clinical trials by decentralizing them, and in particular for those with health conditions that may hinder their ability to visit clinical trial sites. Direct-to-patient shipments extend the clinical trial environment to patients' homes, increasing accessibility and participation, improve participant retention, and can bring medicines to those most in need.

This concept is not new though. In fact, it gained significant attention during the pandemic when clinical trials could not proceed without remote strategies. The method of direct-to-patient shipping improved patient enrollment, reduced dropout rates, and increased diversity in clinical trials.

Key considerations for executing a decentralized trial

Three crucial factors must be considered in direct-to-patient shipments:

  1. Adherence to good clinical practice.
  2. Ensuring data privacy.
  3. Maintaining the integrity of the investigational medicine product (IMP) during transit.

Addressing these challenges

Technological advancements can help overcome many of these challenges. Real-time tracking, secure data transmission, and temperature-controlled packaging are all solutions that can be leveraged to improve DtP shipments. However, the absence of specific regulations for DtP shipments remains a challenge. It is important for the industry and regulatory bodies to work together to establish robust legislation that accommodates this patient-centric model.

The future of direct-to-patient

The adoption of a DtP model for executing decentralized clinical trials is expected to increase. With the right regulations, technological advancements, and an emphasis on patient centricity, this method can revolutionize the conduct of clinical trials.

Key takeaways

The ultimate goal of decentralized trials is patient centricity. By improving accessibility and diversity, this method not only benefits the participants but can also help bring life-saving drugs to the market faster for the benefit of all patients

Listen to the full podcast now


It's got to be cold, fast, and efficient

What to consider when selecting shipping for your specialty drug product

by Christopher Engel M.Sc.

Demand for advanced cold-chain logistics is increasing as more and more treatments, from vaccines to cell and gene therapies (CGTs), are requiring complex temperature-controlled transport and storage. With the right logistics supplier, it is possible to implement an effective cold-chain supply strategy to meet your unique needs. But how do you find the best logistics partner? What actions are needed to fully understand the capabilities of potential suppliers?

Get our infographic now for the five golden rules to follow to get the customizable shipping solutions your products need.


Six considerations when bringing your new product to market

Unlock the full potential of your product and make the most of your investments by following our latest step-by-step guide to commercialization.

Having devoted your time, expertise, and financial resources to the development of a transformative cell or gene therapy that improves patients’ lives, ensuring that patients can truly reap the benefits of your innovation is essential.

Our latest guide is a treasure trove of knowledge, including:

  • Valuable insights to help you navigate the market and maximize the impact of your therapy.
  • Six key considerations for commercializing your CGT asset, from patient access and support, to regulations, logistics and supply chain, commercial distribution, and more.

Get it now and kick off commercialization success


In case you haven't heard, we are now Cencora.

By unifying all organizations under one banner, it combines resources for broader equity, sustainability, and impact in healthcare.

The name — a blend of center and core — is inspired by our customers, their patients, and our 46,000+ team members across the globe who are central to everything we do.

Our strength as a purpose-driven and partner-centric organization enables us to drive improved global access and better patient outcomes.

Discover how this transformation unites us in our shared purpose.


Why choose World Courier?

Start a conversation now


要查看或添加评论,请登录

社区洞察

其他会员也浏览了